Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04100174 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Focal HDR Brachytherapy Boost to Stereotactic Radiotherapy

Study acronym: fBTsRT
StatusRecruiting
PhasePhase 2
Started2019-07-01
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 13, 2025 (before its estimated May 30, 2025 completion). Its status may not reflect the trial's current state.

Amendment history

2025-03-12
Study Status v5
Primary completion date2024-10-30→2025-05-30
2023-10-17
Study Status v4
Primary completion date2023-06-30→2024-10-30
2022-11-09
Study Status, Study Description, Contacts/Locations v3
Primary completion date2022-06-30→2023-06-30
Completion date2022-06-30→2025-06-30
Study sites1→2
Study descriptionrevised
[...] rinary irritation/obstructive QoL as measured by ePRO (EPIC-CP26) at 12 and 24 months post completion of therapy.
2021-01-25
Study Status v2
Re-verified, no change to tracked fields
2019-09-24
Study Status, Study Description, Eligibility, Contacts/Locations, IPDSharing v1
Eligibility criteria+17 characters
[...] % of the prostate gland and consistent with biopsy findings. Exclusion - none
Study description+11 characters
In this Phase IIR trial weinvestigators primarily seek to determine if fBT boost (15Gy) to SBRT (35 [...]
2019-09-20
Original filing
To determine if fBT+sRT is superior to standard care in terms of urinary toxicity by having fewer patients experience a minimal important decline (MID) in urinary irritation/obstructive QoL
Trial Details
NCT Number NCT04100174
Lead Sponsor Centre hospitalier de l'Université de Montréal (CHUM)
Conditions Prostate Cancer
Enrollment 150 participants
Start Date 2019-07-01
Primary Completion 2025-05-30 (estimated)
Study Completion 2025-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-03-13